Skip to main content

Abstract

The abbreviated impactor measurement (AIM) and efficient data analysis (EDA) concepts for the in vitro assessment of orally inhaled drug products (OIPs), comprising pressurized metered-dose inhalers (MDIs), soft mist inhalers (SMIs), dry powder inhalers (DPIs), and nebulizing systems, are the topics covered by this book. The chief aims are to provide to potential adoptees of these new methods answers to “how to” questions, as well as to those charged with regulatory oversight assurance that both concepts are fully founded on valid scientific principles. A ­chapter reviewing the cascade impaction method applied to the assessment of OIPs is also included in order to provide the reader with the necessary background material before exploring the extensions to current methodologies associated with AIM and EDA. Both concepts are related, but do not necessarily need to be applied together, nor is AIM an all-purpose replacement for OIP aerodynamic particle size distribution (APSD) measurements by full-resolution cascade impactor (CI).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bonam M, Christopher D, Cipolla D, Donovan B, Goodwin D, Holmes S, Lyapustina S, Mitchell J, Nichols S, Petterson G, Quale C, Rao N, Singh D, Tougas T, Van Oort M, Walther B, Wyka B (2008) Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSciTech 9(2):404–413

    Article  PubMed  CAS  Google Scholar 

  2. Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 16(4):341–377

    Article  PubMed  CAS  Google Scholar 

  3. Rudolph G, Köbrich R, Stahlhofen W (1990) Modeling and algebraic formulation of regional aerosol deposition in man. J Aerosol Sci 21(S1):S403–S406

    Article  Google Scholar 

  4. Heyder J, Svartengren MU (2002) Basic principles of particle behavior in the human respiratory tract. In: Bisgaard H, O’Callaghan C, Smaldone GC (eds) Drug delivery to the lung. Dekker, New York, NY

    Google Scholar 

  5. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S, Mitchell J, Rogers B, Strickland H, Tougas T, Tsong Y, Wyka B (2003) Considerations for the development and practice of cascade impaction testing including a mass balance failure investigation tree. J Aerosol Med 16:235–247

    Article  PubMed  Google Scholar 

  6. Van Oort M, Roberts W (1996) Variable stage-variable volume strategy for cascade impaction. In: Dalby RN, Byron PR, Farr EJ (eds) Respiratory drug delivery-V. Interpharm Press, Buffalo Grove, IL, pp 418–421

    Google Scholar 

  7. Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med 18(4):439–451

    Article  PubMed  CAS  Google Scholar 

  8. European Directorate for the Quality of Medicines and Healthcare (EDQM) (2012) Preparations for inhalation: aerodynamic assessment of fine particles, Chapter 2.9.18. In: European Pharmacopeia, 7th edn. Strasbourg, France

    Google Scholar 

  9. United States Pharmacopeial Convention (USP) (2012) Aerosols, metered-dose inhalers, and dry powder inhalers USP35-NF30, Chapter 601. Rockville, MD

    Google Scholar 

  10. Mitchell JP, Dolovich MB (2012) Clinically relevant test methods to establish in vitro equivalence for spacers and valved holding chambers used with pressurized metered dose inhalers (pMDIs). J Aerosol Med Pulm Deliv 25(4):217–242

    Article  CAS  Google Scholar 

  11. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S (2009) Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). AAPS PharmSciTech 10(4):1276–1285

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Terrence P. Tougas .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tougas, T.P., Mitchell, J.P., Morgan, B., Strickland, H. (2013). Introduction. In: Tougas, T., Mitchell, J., Lyapustina, S. (eds) Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-6296-5_1

Download citation

Publish with us

Policies and ethics